Advances in Traditional Medicine

Kyung Hee Oriental Medicine Research Center (경희대학교 융합한의과학연구소)
권호 표지
DOI QR코드

DOI QR Code

Cardioprotective effect of Argyreia speciosa (Burm. f) Boj. extracts against Isoproterenol- induced myocardial infarction in rats

  • Thakker, Shalin (Department of Pharmaceuticeutical technology, Postgraduate Studies and Research Center, SET's College of Phamacy) ;
  • Biradar, S.M. (Department of Pharmacology, Postgraduate Studies and Research Center, SET's College of Phamacy) ;
  • Habbu, P.V. (Department of Pharmacognosy, Postgraduate Studies and Research Center, SET's College of Phamacy) ;
  • Mahadevan, K.M. (Department of Chemistry, School of Chemical Sciences, Kuvempu University) ;
  • Thippeswamy, B.S. (Department of Pharmacology, Postgraduate Studies and Research Center, SET's College of Phamacy) ;
  • Veerapur, V.P. (Department of Pharmaceutical Chemistry, Postgraduate Studies and Research Center, SET's College of Phamacy)
  • Received : 2010.07.03
  • Accepted : 2010.12.07
  • Published : 2010.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The present study was undertaken to evaluate the protective effect of ethanol (EtAS), ethyl acetate (EAAS) and aqueous (AQAS) extracts of Argyreia speciosa (AS) roots against Isoproterenol (ISO)-induced myocardial infarction in rats. The animals were exposed to isoproterenol (200 mg/kg. s.c) twice at an interval of 24 hrs. Cardioprotective effect was assessed by observing ECG parameters, serum marker enzymes and histopathology of the heart. Pretreatment of EAAS, and EtAS (200 mg/kg) resulted in a significant (P < 0.001) increase in P wave, QRS complex and R-R interval, whereas heart rate, QT interval and cardiac cycle were maintained near to normal values. EtAS and EAAS showed significant (P < 0.05; P < 0.001) reduction in all the tested diagnostic markers compared to ISO treated group. Histological studies on the structural changes of heart tissue supported the protective activity of AS. The result suggest that treatment of AS prior to ISO has a significant role in protecting the animals from ISO induced myocardial infarction.

Keywords

References

  1. Dhalla NS, Temsah RM, Netticadan T. (2000) Role of oxidative stress in cardiovascular diseases. J. Hypertension. 18, 655–673. https://doi.org/10.1097/00004872-200018060-00002
  2. Francis Morris, June Edhouse, William J Brady, John Camm. (2003) ABC OF CLINICAL ELECTROCARDIOGRAPHY, Chapter 8 Acute myocardial infarction-Part I 29-30. BMJ Publishing Group.
  3. Gokhale AB, Damre AS & Saraf MN. (2003) Investigations in to the Immunomodulatory activity of Argyreia speciosa. J. Ethnopharmacol. 84, 109-114. https://doi.org/10.1016/S0378-8741(02)00168-X
  4. Gokhale AB, Damre AS, Kulkarni KR & Saraf MN. (2002) Preliminary evaluation of anti-inflammatory and anti-arthritic activity of S. lappa, A. speciosa and A. aspera. Phytomed. 9, 433-437. https://doi.org/10.1078/09447110260571689
  5. Gurgun C, Ildizli M, Yavuzgil O, Sin A, Apaydin A, Cinar C, Kultursay H. (2008) The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int. J. Cardiol. 123, 102–107.
  6. Habbu PV, Mahadevan KM, Kulkarni VH, Marietta P, Pratap V, Thippeswamy BS & Veerapur VP. (2010) Antidiabetic activity of Argyreia speciosa (sweet) (Burm.f.)Boj. in normoglycemic and Streptozotocininduced diabetic rats. Orient. Pharm. Experment. Med. 10, 90-102. https://doi.org/10.3742/OPEM.2010.10.2.090
  7. Habbu PV, Shastry RA, Mahadevan KM, Joshi HK & Das SK. (2008) Hepatoprotective and antioxidant effects of Argyreia speciosa in rats, Afr.J .Trad. Compl. Altern. Med. 5, 158-164.
  8. Habbu PV, Shastry RA, Mahadevan KM & Sneha C (2009) Antiamnesic activity of Argyreia speciosa in mice. Int. J. Green Pharm. 4, 83-89.
  9. Habbu PV, Shastry RA, Mahadevan KM, Manjunath H. (2009) Antimicrobial activity of flavanoids sulphates and other fractions of Argyreia speciosa (Burm.f.) Boj. Ind. J. Exp. Bio. 47, 121-127.
  10. Hevener A, Reichart D, Janez A, Olefsky J. (2002) Female rats do not exhibit free fatty acid–induced insulin resistance. Diabetes. 51, 1907–1912.
  11. Holland RP, Brooks H. (1977) TQ-ST segment mapping: critical review and analysis of current concepts. Am. J. Cardiol. 40, 110-129. https://doi.org/10.1016/0002-9149(77)90109-6
  12. Karthick M, Stanely, Mainzen Prince P. (2006) Preventive effect of rutin, a bioflavonoid, on lipid peroxides and antioxidants in ISO-induced myocardial infarction in rats. J. Pharm. Pharmacol. 58, 701-707. https://doi.org/10.1211/jpp.58.5.0016
  13. Kela AK, Reddy LP, Thrombe DP. (1980) ECG findings in normal rats and after administration of isoproterenol. Ind. J. Physio.l Pharmacol. 24, 84-90.
  14. Linz W, Wiemer G, Schaper J, Zimmermann R, Nagasawa K, Gohlke P, Unger T. (1995) Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Mol. Cell Biochem. 147, 89–90.
  15. Lopez AD, Murray CC. (1998) The global burden disease, 1990-2020. Nat Med. 4, 1241-1243. https://doi.org/10.1038/3218
  16. Mochizuki S, Takeda N, Nagano M, Dhalla, NS. (1998) The ischemic heart. In: Mochizuki S. (Ed) Kluwer Academic Publishers.
  17. Padmanabhan M, Stanely, Mainzen Prince. (2007) Sallylcysteine ameliorates isoproterenol-induced cardiac toxicity in rats by stabilizing cardiac mitochondrial and lysosomal enzymes. Life sciences. 80, 972-978. https://doi.org/10.1016/j.lfs.2006.11.028
  18. Paritha, Ithayarshi, Padmavathy V., Shyamala, Devi CS. (1996) Effect of $\alpha$-tocopherol on isoproterenolinduced Myocardial Infarction in rats-Electrocardiographic Biochemical and histological evidences. Ind. J. Physiol. Pharmacol. 40, 297-302.
  19. Peacock WF, Hollander JE, Smalling RW, Bresler MJ. (2007) Reperfusion strategies in the emergency treatment of ST-segment elevation myocardial infarction. Am. J. Emerg. Med. 25, 353-366. https://doi.org/10.1016/j.ajem.2006.07.013
  20. Petra M, Britta T, Macki K, Eckart E. (1999) Flavanoid sulphates from Convolvulaceae. Phytochem. 50, 267-271. https://doi.org/10.1016/S0031-9422(98)00502-0
  21. Rajadurai M, Stanely, Mainzen Prince P. (2006) Preventive effect of naringin on lipid peroxides and antioxidants in isoproterenol-induced cardiotoxicity in Wistar rats: biochemical and histopathological evidences. Toxicol. 228, 259–268.
  22. Rajadurai M, Stanely, Mainzen Prince P. (2007) Preventive effect of naringin on cardiac markers, electrocardiographic patterns and lysosomal hydrolases in normal and isoproterenol-induced myocardial infarction in Wistar rats. Toxicol. 230, 178-188. https://doi.org/10.1016/j.tox.2006.11.053
  23. Rathore N, John S, Kale M, Bhatnagar D. (1998) Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues. Pharmacol. Res. 38, 297–303.
  24. Sabeena, Farvin KH, Anandan R, Kumar SH, Shiny KS, Sankar TV, Thankappan TK. (2004) Effect of squalene on tissue defense system in isoproterenolinduced myocardial infarction in rats. Pharmacol. Res. 50, 231-236. https://doi.org/10.1016/j.phrs.2004.03.004
  25. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. (2002) Role of oxidative stress in myocardial hypertrophy and failure. J. Mol. Cell Cardiol. 34, 379–388.
  26. Seneviratine CK, Timao Li, Khaper N, Singal PK. (1999) Effects of methionine on endogenous antioxidants in the heart. Am. J. Physiol. 277 (Heart Circ Physiol 46), H2122-H2128.
  27. Sharma PC, Yelne, MB & Dennis TJ. (2004) Database on medicinal plants used in Ayurveda. pp 550, Central Council for Research in Ayurveda and Siddha New Delhi.
  28. Srivastava A, Shukla Y. (1998) Aryl esters and a Coumarin from Argyreia speciosa, Ind. J. Chem. 37, 192-194. https://doi.org/10.1021/ie9703898
  29. Srivastava S, Chandrasekar B, Gu Y, Luo J, Hamid T, Hill BG, Prabhu SD. (2007) Down regulation of Cu, Zn-superoxide dismutase contributes to betaadrenergic receptor-mediated oxidative stress in the heart. Cardiovasc. Res. 74, 445-455. https://doi.org/10.1016/j.cardiores.2007.02.016
  30. Stauss HM, Zhu YC, Redlich T, Adamiak D, Mott A, Kregel KC, Unger T. (1994) Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J. Cardiovasc. Risk. 1, 255–262. https://doi.org/10.1177/174182679400100311
  31. Todd GL, Cullan GM. (1980) Isoproterenol-induced myocardial necrosis and membrane permeability alterations in the isolated perfused rabbit heart. Experim. Mol. Path. 33, 43-45. https://doi.org/10.1016/0014-4800(80)90006-4
  32. Varier PK. (1995) Indian medicinal plants. A compendium of 500 species. Vol. 2, pp235-237 Orient Longman Madras.
  33. Warrier PK, Nambiar VP, Ramankutty C. (1994) Indian medicinal plants-a compendium of 500 species. pp191. Orient Longman New Delhi.
  34. Wexler BC. (1973) Protective effects of propanolol in isoproterenol induced myocardial infarction. Atheroscler. 18, 11-14. https://doi.org/10.1016/0021-9150(73)90114-7
  35. Wexler BC. (1978) Myocardial infarction in young vs old male rats: Pathophysiological changes. Am. Hear.t J. 96, 70-80. https://doi.org/10.1016/0002-8703(78)90128-X
  36. White HD. (1996) Myocardial infarction. In: Julian DG, Camm AJ, Fox KM, Hall RJC, Poole Wilson PA (Ed) Diseases of the heart. pp1042-1075. W.B Saunders Company Ltd London.
  37. Young IS, Purvis JA, Lightbody JH, Adgey AA, Trimble ER. (1993) Lipid peroxidation & antioxidant status following thrombolytic therapy for acute myocardial infarction. Eur. Heart. J. 14, 1027-1033. https://doi.org/10.1093/eurheartj/14.8.1027
  38. Zaijun Zhang, Jie Jiang, Pei Yu1, Xiangping Zeng, James W Larrick. Yuqiang Wang. (2009) Hypoglycemic and beta cell protective effects of andrographolide analogue for diabetes treatment. J. Translat. Med. 7:62, doi:10.1186/1479-5876-7-62.
  39. Zhou B, Wu LJ, Li LH, Tashiro S, Onodera S, Uchiumi F, Ikejima T, (2006) Silibinin protects against isoproterenol-induced rat cardiac myocyte injury through mitochondrial pathway after up-regulation of SIRT1. J. Pharmacol. Sci. 102, 387–395.
  40. Zhu YZ, Zhu YC, Gohlke P, Unger T. (1998) Overview on pharmacological properties of angiotensin converting enzyme inhibitors. In: Hall AS, Unger T (Eds). ACE Inhibition and Target Organ Protection. Euromed Communications Ltd, 1–20.
  41. Zhu YC, Zhu YZ, Gohlke P, Unger T. (1997) Effects of converting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Am. J. Cardiol. 80, 110A–117A.
  42. Zhu YC, Zhu YZ, Spitznagel H, Gohlke P, Unger T. (1996) Substrate metabolism, hormone interaction and angiotensin converting enzyme inhibition in left ventricular hypertrophy. Diabetes. 45, S59–S65.